Clinical trial
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
NCT00476229 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00476229 |
|---|---|
| Title | Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies |
| Official title | Total Lymphoid Irradiation, Thymoglobulin, and Rituximab for Allogeneic Transplantation in Lymphoid Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Lymphoma, Leukemia |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | Thymoglobulin, Total Lymphoid Irradiation, Peripheral Blood Stem Cell Infusion, Rituximab |
| Enrollment | 20 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | May 21, 2007 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: